These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 39351819)

  • 1. Pharmacokinetic comparison of subcutaneously administered CT-P13 (biosimilar of infliximab) via autoinjector and pre-filled syringe in healthy participants.
    Park YC; Kim JH; Kim SH; Lee JH; Hong JH; Jung JG; Sunwoo J
    Clin Transl Sci; 2024 Oct; 17(10):e70037. PubMed ID: 39351819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study.
    Yu KS; Ryu H; Shin D; Park M; Hwang J; Moon SJ; Kim MG; Keystone E; Smolen JS; Kim S; Bae Y; Jeon D; Jang J; Yang G; Bae J; Lee J; Burmester GR
    Expert Opin Biol Ther; 2024 Jul; 24(7):681-689. PubMed ID: 38905143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects.
    Shin D; Lee Y; Jeong D; Ellis-Pegler R
    Drug Des Devel Ther; 2018; 12():3799-3805. PubMed ID: 30464411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects.
    Bush J; Kawakami K; Muniz R
    BMC Pharmacol Toxicol; 2019 Dec; 20(1):87. PubMed ID: 31888742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects.
    Davidson A; Brimhall D; Kay J; Keystone E; Lee SJ; Kim SH; Bae YJ; Choi EJ; Furst DE
    Br J Clin Pharmacol; 2021 Nov; 87(11):4323-4333. PubMed ID: 33822406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease.
    Schreiber S; Ben-Horin S; Leszczyszyn J; Dudkowiak R; Lahat A; Gawdis-Wojnarska B; Pukitis A; Horynski M; Farkas K; Kierkus J; Kowalski M; Lee SJ; Kim SH; Suh JH; Kim MR; Lee SG; Ye BD; Reinisch W
    Gastroenterology; 2021 Jun; 160(7):2340-2353. PubMed ID: 33676969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Pharmacokinetics, Safety, and Tolerability of the Autoinjector (AI) and Pre-Filled Syringe (PFS) of SB4 in Healthy Subjects.
    Shin D; Kim Y; Go A; Velinova M
    Drug Des Devel Ther; 2020; 14():43-50. PubMed ID: 32021090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and Pharmacodynamic Bioequivalence of Pegfilgrastim-cbqv Delivered via a Prefilled Autoinjector and Prefilled Syringe in Healthy Male Participants.
    Tang H; Civoli F; Tatarewicz S; Vandenkoornhuyse N; Finck B
    Adv Ther; 2023 Nov; 40(11):4889-4906. PubMed ID: 37707674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic Similarity of ABP 710, a Proposed Biosimilar to Infliximab: Results From a Randomized, Single-Blind, Single-Dose, Parallel-Group Study in Healthy Subjects.
    Chow V; Oh M; Gessner MA; Fanjiang G
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):246-255. PubMed ID: 31628783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY).
    Hanauer SB; Sands BE; Schreiber S; Danese S; Kłopocka M; Kierkuś J; Kulynych R; Gonciarz M; Sołtysiak A; Smoliński P; Srećković S; Valuyskikh E; Lahat A; Horyński M; Gasbarrini A; Osipenko M; Borzan V; Kowalski M; Saenko D; Sardinov R; Lee SJ; Kim S; Bae Y; Lee S; Lee S; Lee JH; Yang S; Lee J; Lee J; Kim JM; Park G; Sandborn WJ; Colombel JF
    Gastroenterology; 2024 Oct; 167(5):919-933. PubMed ID: 38788861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study.
    Park W; Lee SJ; Yun J; Yoo DH
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S25-31. PubMed ID: 26395834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes.
    von Richter O; Skerjanec A; Afonso M; Sanguino Heinrich S; Poetzl J; Woehling H; Velinova M; Koch A; Kollins D; Macke L; Wuerth G
    Br J Clin Pharmacol; 2017 Apr; 83(4):732-741. PubMed ID: 27790726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized, Open-Label Study Conducted to Evaluate the Bioequivalence of Pegfilgrastim-cbqv On-Body Injector Versus Prefilled Syringe in Healthy Male Participants.
    Tang H; Civoli F; Tatarewicz S; Vandenkoornhuyse N; Finck B
    Adv Ther; 2024 Mar; 41(3):991-1009. PubMed ID: 38180721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tezepelumab Pharmacokinetics, Safety, and Tolerability After Administration via Vial-and-syringe, Accessorized Prefilled Syringe, or Autoinjector: A Randomized Trial in Healthy Volunteers.
    Zheng Y; Abuqayyas L; Megally A; Fuhr R; Sałapa K; Downie J; Colice G
    Clin Ther; 2021 Jan; 43(1):142-155.e5. PubMed ID: 33380362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and tolerability of prefilled syringe and auto-injector presentations of MSB11456: results of a randomized, single-dose study in healthy adults.
    Tomaszewska-Kiecana M; Dryja A; Ullmann M; Petit-Frere C; Illes A; Dagres C; Monnet J
    Expert Rev Clin Immunol; 2023 Apr; 19(4):447-455. PubMed ID: 36789991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
    Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
    Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters.
    Kim H; Alten R; Cummings F; Danese S; D'Haens G; Emery P; Ghosh S; Gilletta de Saint Joseph C; Lee J; Lindsay JO; Nikiphorou E; Parker B; Schreiber S; Simoens S; Westhovens R; Jeong JH; Peyrin-Biroulet L
    MAbs; 2021; 13(1):1868078. PubMed ID: 33557682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects.
    Zhang T; Chen G; Liu C; Zu L; Wang Q; Wang Y; Lv J; An Y; Dong L; Cheng H; Ren S; Wang Q; Zheng Q; Song H; Fang Y
    BioDrugs; 2019 Feb; 33(1):93-100. PubMed ID: 30511316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized, Phase I Pharmacokinetic Study Comparing SB2 and Infliximab Reference Product (Remicade(®)) in Healthy Subjects.
    Shin D; Kim Y; Kim YS; Körnicke T; Fuhr R
    BioDrugs; 2015 Dec; 29(6):381-8. PubMed ID: 26577771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.